Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used
control group:Follow the guidelines for standard treatment
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) aged 18-80 years old; (2) severe (including critical risk factors) and critical patients with confirmed novel coronavirus pneumonia; (3) blood CRP and ESR were more than twice higher than normal or TNFa and Il-6 were higher than normal; (4) sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) pregnant or breast-feeding women; (2) ALT/AST > 5 times ULN, neutrophils < 0.5x10^9/L, platelets less than 50x10^9/L; (3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases; (4) patients with long-term oral immunoregulatory drugs or who had used large doses of glucocorticoids within 14 days; (5) allergic reactions to adamumab or tozumab; (6) active hepatitis, tuberculosis, associated with specific severe bacterial and fungal infections, organ transplantation or mental disorders; (7) received Il-6 monoclonal antibody or TNFa monoclonal antibody within 14 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10; | — |
Countries
China
Contacts
Public ContactMin Zhang
Shanghai General Hospital
Outcome results
None listed